Business
Tilray Medical Publishes Pioneering Research on the Pharmacokinetics of THC and CBD Formulations
New Study Provides Insight into the Bioavailability of Medical Cannabis Formulations for Therapeutic Treatment NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) --
About this update from Tilray Brands, Inc.
[{"type":"text","content":"New Study Provides Insight into the Bioavailability of Medical Cannabis Formulations for Therapeutic Treatment\nNEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. (\"Tilray\" or the \"Company\") (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, today announced the publication of a scientific study. This new research focuses on comparing the bioavailability of different cannabinoid formulations, taking a step forward in our understanding of medical cannabis. The study aimed to assess the pharmacokinetic parameters and relative bioavailability of two D9-tetrahydrocannabinol: cannabidiol (THC:CBD) formulations. (A) An orally administered: Tilray THC:CBD extract and (B) an oromucosally administered nabiximols formulation. This pilot crossover study counterbalanced (1) 1 mL of orally administered Tilray THC:CBD extract (10 mg/mL each of THC and CBD) and (2) oromucosally administered nabiximols (four sprays of 2.7 mg THC and 2.5 mg CBD per spray, for a total dose of 10.8 mg THC and 10 mg CBD). Blood samples were obtained pre-dose and at 16 post-dose time points over 24 hours. Pharmacokinetic parameters were calculated for THC, 11-hydroxy-tetrahydrocannabinol (11-OH-THC), and CBD. Conducted with twelve healthy volunteers (6 male, 6 female) under fasting conditions, the results revealed that the Cmax for THC and CBD was significantly higher for the Tilray THC:CBD extract compared to nabiximols and neither Tmax nor AUC was significantly different for the two treatments. Interestingly, the Cmax for nabiximols was significantly higher in males compared to females. Under both treatment conditions, THC and CBD were undetectable 24 hours post-dose, and 11-OH-THC was markedly reduced from its peak. Notably, no serious adverse events were reported. This pilot study shows that oral administration of Tilray THC:CBD extract formulation achieved higher THC and CBD concentrations within a shorter timeframe compared to the oromucosal delivery of nabiximols. These findings may have significant implications for clinical populations using these formulations therapeutically. José Tempero, Tilray’s Medical Director, remarked, \"By advancing our understanding of canna...